Luye Pharma Group Ltd. (HKG:2186)

Luye Pharma Group Revenue

Luye Pharma Group had revenue of 3.00B CNY in the half year ending June 30, 2026, a decrease of -2.36%. This brings the company's total for the last twelve months to 6.13B, down -0.63% year-over-year. In the year 2025, Luye Pharma Group had annual revenue of 6.31B with 4.07% growth. That makes Luye Pharma Group the 8,081st largest company in the world by revenue and 497th in Hong Kong.

• Revenue (ttm): 6.13B CNY
• Revenue Growth: -0.63%
• P/S Ratio: 0.96
• Revenue / Employee: 1.16M CNY
• Employees: 5,270
• Market Cap: 6.31B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Segment

By Segment

Chart

• Oncology Drugs 2.30B 36.4%
• Central Nervous System Drugs 2.03B 32.1%
• Cardio-Vascular System Drugs 1.15B 18.3%
• Others 482.05M 7.6%
• Alimentary Tract and Metabolism Drugs 348.76M 5.5%

By Geography

Chart

• Mainland China 5.14B 81.4%
• European Union 538.99M 8.5%
• Asia (Other than Chinese Mainland) 499.10M 7.9%
• Other Countries 134.49M 2.1%

Fiscal year ended Dec 31, 2025 See the full Luye Pharma Group breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	6.31B	246.93M	4.07%
Dec 31, 2024	6.06B	-81.64M	-1.33%
Dec 31, 2023	6.14B	161.42M	2.70%
Dec 31, 2022	5.98B	781.43M	15.03%
Dec 31, 2021	5.20B	-339.42M	-6.13%

Data Source: S&P Global Market Intelligence Last updated: Sep 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 21, 2026

Data Sources Report a data error